Identifying tumor vascular permeability heterogeneity with magnetic resonance imaging contrast agents

被引:20
作者
Aref, M
Brechbiel, M
Wiener, EC
机构
[1] Univ Illinois, Beckman Inst 4247, Urbana, IL 61801 USA
[2] Univ Illinois, Dept Nucl Plasma & Radiol Engn, Urbana, IL 61801 USA
[3] Univ Illinois, Biomed Magnet Resonance Facil, Urbana, IL 61801 USA
[4] Univ Illinois, Dept Med Informat Sci, Urbana, IL 61801 USA
[5] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA
[6] NCI, NIH, Bethesda, MD 20892 USA
关键词
contrast agents; mammary tumors; permeability; MRI;
D O I
10.1097/00004424-200204000-00003
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
RATIONALE AND OBJECTIVES. Dynamic contrast enhanced (DCE) MR mammography (MRM) uses tumor capillary density differences for prognosis. The heterogeneous response of permeability-surface area products (PS = Kp<---->t) was examined in mammary tumors, as a function of contrast agent size, to determine what effect ROI size might have on PS and prognosis. METHODS. DCE FLASH signal intensities were converted to gadolinium concentrations by a standard curve, which was fitted by a two-compartment model for the tumor's extravascular extracellular space (EES) volume fraction (v(e)), and the tumor volume normalized transfer rate between plasma and EES(Kp<---->tVT). RESULTS. For Gd-DTPA v(e) = 9% to 13% Kp<---->t/V-T = 0.01 to 0.06 minutes(-1), and the macromolecular agent, PAMAMTU-DTPA G = 4 v(e) = 0.8% to 1% Kp<---->t/V-T = 0.008 to 0.04 minutes(-1). Significant differences in Kp<---->t/V-T for local regions were found for both agents relative to the whole tumor and the macromolecular agent had greater dynamic range. CONCLUSIONS. Smaller ROI values or pixels should yield more accurate assessment of neovascularization.
引用
收藏
页码:178 / 192
页数:15
相关论文
共 43 条
  • [1] Imaging breasts with silicone implants
    Azavedo, E
    Boné, B
    [J]. EUROPEAN RADIOLOGY, 1999, 9 (02) : 349 - 355
  • [2] TRANSPORT OF FLUID AND MACROMOLECULES IN TUMORS .4. A MICROSCOPIC MODEL OF THE PERIVASCULAR DISTRIBUTION
    BAXTER, LT
    JAIN, RK
    [J]. MICROVASCULAR RESEARCH, 1991, 41 (02) : 252 - 272
  • [3] Contrast-enhanced MR imaging as a prognostic indicator of breast cancer
    Boné, B
    Aspelin, P
    Bronge, L
    Veress, B
    [J]. ACTA RADIOLOGICA, 1998, 39 (03) : 279 - 284
  • [4] RATIONALE AND APPLICATIONS FOR MACROMOLECULAR GD-BASED CONTRAST AGENTS
    BRASCH, RC
    [J]. MAGNETIC RESONANCE IN MEDICINE, 1991, 22 (02) : 282 - 287
  • [5] PHARMACOKINETIC PARAMETERS IN CNS GD-DTPA ENHANCED MR IMAGING
    BRIX, G
    SEMMLER, W
    PORT, R
    SCHAD, LR
    LAYER, G
    LORENZ, WJ
    [J]. JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1991, 15 (04) : 621 - 628
  • [6] Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesions
    denBoer, JA
    Hoenderop, RKKM
    Smink, J
    Dornseiffen, G
    Koch, PWAA
    Mulder, JH
    Slump, CH
    Volker, EDP
    deVos, RAI
    [J]. JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1997, 7 (04): : 702 - 715
  • [7] Dynamic contrast enhanced Magnetic Resonance Imaging of the breast is superior to triple assessment for the pre-operative detection of multifocal breast cancer
    Drew, PJ
    Chatterjee, S
    Turnbull, LW
    Read, J
    Carleton, PJ
    Fox, JN
    Monson, JRT
    Kerin, MJ
    [J]. ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (06) : 599 - 603
  • [8] Edell S L, 1999, Del Med J, V71, P377
  • [9] ANGIOGENESIS AND BREAST-CANCER
    FOLKMAN, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) : 441 - 443
  • [10] Harms S E, 1996, Curr Probl Diagn Radiol, V25, P193